Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

Cancer alters the function of multiple organs beyond those targeted by metastasis,. Here we
show that inflammation, fatty liver and dysregulated metabolism are hallmarks of …

Ras is frequently mutated in cancer, however, there is a lack of consensus in the literature
regarding the cancer mutation frequency of Ras, with quoted values varying from 10%–30 …

Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

ABSTRACT RAS proteins (KRAS4A, KRAS4B, NRAS and HRAS) function as GDP–GTP-
regulated binary on-off switches, which regulate cytoplasmic signaling networks that control …

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …

The three RAS genes—HRAS, NRAS and KRAS—are collectively mutated in one-third of
human cancers, where they act as prototypic oncogenes. Interestingly, there are rather …

Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly
a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy …

Mutational hotspots indicate selective pressure across a population of tumor samples, but
their prevalence within and across cancer types is incompletely characterized. An approach …